Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the most undervalued large cap stocks to buy according to analysts. On ...

Regeneron's bid to join the US market for BCMA-targeted bispecific antibodies for multiple myeloma has finally been realised after the FDA approved its Lynozyfic drug at a second attempt.

In other recent news, Regeneron Pharmaceuticals received accelerated approval from the U.S. Food and Drug Administration for Lynozyfic, a treatment for adult patients with relapsed or refractory ...

Regeneron Pharmaceuticals announced that the FDA has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt), a bispecific antibody treatment for adult patients with relapsed or ...

Regeneron will market its new product under the brand name Lynozyfic. Lynozyfic came from VelocImmune, a proprietary Regeneron technology that generates fully human antibodies for targets of interest.

U.S. FDA approves Regeneron's blood cancer therapy Regeneron estimates about 4,000 new cases will be among those who have received four or more lines of treatment Updated - July 04, 2025 01:43 pm IST ...

Regeneron has re-filed for FDA approval of Lynozyfic, with a decision expected in July 2025, positioning it as a potential competitor to Tecvayli and Elrexfio. Story Continues Terms ...

About 45% of patients receiving Lynozyfic had no measurable sign of cancer after treatment, according to a news release from Regeneron Pharmaceuticals, the drug’s maker.

Investing.com -- Regeneron Pharmaceuticals (NASDAQ: REGN) stock rose 2.8% after the U.S. Food and Drug Administration granted accelerated approval for the company’s blood cancer therapy Lynozyfic. The ...

Regeneron is committed to helping patients who have been prescribed Lynozyfic access their medication. The company has launched Lynozyfic Surround™, which offers financial and educational resources to ...